Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Total Non-Current Liabilities (2018 - 2025)

Addex Therapeutics' Total Non-Current Liabilities history spans 8 years, with the latest figure at $498736.3 for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 119.62% to $498736.3 in Q4 2025 year-over-year; TTM through Dec 2025 was $498736.3, a 119.62% increase, with the full-year FY2025 number at $480782.1, up 111.71% from a year prior.
  • Total Non-Current Liabilities came in at $498736.3 for Q4 2025, up from $246706.6 in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $1.7 million in Q1 2021, with the low at $39280.8 in Q1 2023.
  • Historically, Total Non-Current Liabilities has averaged $534425.3 across 5 years, with a median of $239354.0 in 2025.
  • Peak annual rise in Total Non-Current Liabilities hit 652.68% in 2023, while the deepest fall reached 95.19% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $1.6 million in 2021, then plummeted by 94.36% to $90337.0 in 2022, then skyrocketed by 652.68% to $679948.1 in 2023, then crashed by 66.6% to $227093.2 in 2024, then skyrocketed by 119.62% to $498736.3 in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ADXN at $498736.3 in Q4 2025, $246706.6 in Q3 2025, and $172538.7 in Q2 2025.